Venlafaxine

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Oberlander, 2008 Einarson, 2009 Furu, 2015 Te Winkel, 2016 Ozturk, 2016 Bérard b (Controls unexposed, sick), 2017 Richardson, 2019 Anderson, 2020 Chan (Controls unexposed, general pop), 2024 91.15[0.93; 1.42]129,9644,889not evaluable Major congenital malformations Oberlander, 2008 Einarson, 2009 Furu, 2015 Te Winkel, 2016 Ozturk, 2016 Bérard b (Controls unexposed, sick), 2017 Richardson, 2019 Anderson, 2020 Chan (Controls unexposed, general pop), 2024 91.17[0.97; 1.41]129,9334,889not evaluable Congenital heart defects Oberlander, 2008 Furu, 2015 Bérard b (Controls unexposed, sick), 2017 Anderson, 2020 Chan (Controls unexposed, general pop), 2024 51.29[0.85; 1.96]35,4073,798not evaluable Cardiac septal defects Furu, 2015 Bérard b (Controls unexposed, sick), 2017 Anderson, 2020 31.21[0.68; 2.14]17,5283,501not evaluable Cleft lip with or without cleft palate Anderson, 2020 11.98[0.95; 4.12]--not evaluable Cleft palate Anderson, 2020 13.39[1.59; 7.22]--not evaluable Craniosynostosis Bérard b (Controls unexposed, sick), 2017 Anderson, 2020 21.33[0.66; 2.67]-738not evaluable Hypoplastic left heart (HLH/HLHS) Anderson, 2020 Kolding (Controls unexposed, disease free), 2021 27.95[1.67; 37.85]--not evaluable Hypospadias Furu, 2015 Anderson, 2020 21.29[0.71; 2.31]4,5332,763not evaluable Oro-facial clefts Anderson, 2020 12.44[1.33; 4.48]--not evaluable Severe congenital heart defect Kolding (Controls unexposed, sick), 2021 11.78[0.67; 4.71]26847not evaluable Atrial septal defect Anderson, 2020 12.26[1.03; 4.96]--not evaluable Coarctation of aorta Anderson, 2020 13.54[1.56; 8.05]--not evaluable Digestive system anomalies Bérard b (Controls unexposed, sick), 2017 10.89[0.44; 1.82]-738not evaluable Eye, ear, face and neck malformations Bérard b (Controls unexposed, sick), 2017 10.70[0.22; 2.21]-738not evaluable Gastroschisis Anderson, 2020 14.71[1.89; 11.75]--not evaluable Genital anomalies Bérard b (Controls unexposed, sick), 2017 10.69[0.29; 1.66]-738not evaluable Limb defects Bérard b (Controls unexposed, sick), 2017 11.30[0.93; 1.81]-738not evaluable Minor congenital malformations Richardson, 2019 10.55[0.17; 1.82]31270not evaluable Nervous system anomalies Bérard b (Controls unexposed, sick), 2017 11.19[0.55; 2.58]-738not evaluable Neural Tube Defects Anderson, 2020 12.62[1.19; 5.76]--not evaluable Pulmonary valve stenosis Anderson, 2020 12.46[1.04; 5.81]--not evaluable Respiratory system anomalies Bérard b (Controls unexposed, sick), 2017 12.17[1.07; 4.39]-738not evaluable Spina bifida Anderson, 2020 11.85[0.63; 5.43]--not evaluable Urinary malformations Bérard b (Controls unexposed, sick), 2017 11.43[0.75; 2.73]-738not evaluable Ventricular septal defect Anderson, 2020 12.09[0.84; 5.20]--not evaluable Growth parameters and prematurity Preterm (< 37 weeks) Calderon-Margalit, 2009 Te Winkel, 2016 Ozturk, 2016 Richardson, 2019 Marks (Controls exposed to Bupropion), 2021 Martin, 2024 61.64[1.33; 2.02]121,2107,381not evaluable Small for gestational age (weight) Richardson, 2019 Martin, 2024 20.91[0.83; 1.00]229,7075,628not evaluable Low birth weight (< 2500g) Calderon-Margalit, 2009 12.14[0.35; 13.19]-9not evaluable Maternal consequences Postpartum hemorrhage Palmsten b, 2013 Hanley, 2016 21.88[1.39; 2.54]23,8412,153not evaluable Preeclampsia Palmsten (Controls unexposed, sick), 2013 11.57[1.29; 1.91]3,3151,113not evaluable Gestational diabetes Dandjinou, 2019 11.27[1.09; 1.48]20,9051,885not evaluable Neonatal disorders Low Apgar score (< 7) (at 5 min) Calderon-Margalit, 2009 Marks (Controls exposed to Bupropion), 2021 Martin, 2024 31.99[1.10; 3.61]31,2755,910not evaluable Neonatal medical care Calderon-Margalit, 2009 Marks (Controls exposed to Bupropion), 2021 21.61[0.59; 4.41]124141not evaluable Persistent pulmonary hypertension Bérard a, 2017 Marks (Controls exposed to Bupropion), 2021 20.89[0.13; 6.37]249551not evaluable Withdrawal syndrome / Neonatal abstinence syndrome / Poor neonatal adaptation Marks (Controls unexposed, sick), 2021 13.95[1.74; 8.97]-57not evaluable Jaundice / Icterus Marks (Controls exposed to Bupropion), 2021 10.86[0.49; 1.51]81132not evaluable Neonatal tachypnea Marks (Controls exposed to Bupropion), 2021 12.36[1.34; 4.13]59132not evaluable Intrauterine deaths Early intrauterine deaths (< 22 weeks) / Spontaneous abortions Einarson, 2001 Yaris, 2005 Nakhai-Pour, 2010 Kjaersgaard (Controls unexposed, sick), 2013 Te Winkel, 2016 Ozturk, 2016 Richardson, 2019 71.73[1.42; 2.11]5,4941,147not evaluable Elective/induced termination of pregnancy Kieler, 2015 Ozturk, 2016 Te Winkel, 2016 Richardson, 2019 41.97[1.19; 3.26]15,1241,026not evaluable Late intrauterine deaths (> 22 weeks) / Stillbirths Te Winkel, 2016 Richardson, 2019 21.51[0.53; 4.28]23946not evaluable Therapeutic terminations of pregnancy Einarson, 2001 Kieler, 2015 22.39[1.25; 4.55]9150not evaluable Neuro-developmental disorders ASD (Autism spectrum disorder): Diagnosis Rai (Controls unexposed, sick), 2017 Heuvelman, 2023 21.60[1.00; 2.57]3641,031not evaluable ASD (Autism spectrum disorder): Diagnosis/Risk Rai (Controls unexposed, sick), 2017 Heuvelman, 2023 21.60[1.00; 2.57]3641,031not evaluable Cognitive developmental disorders/delay (3-6 years old) Nulman (Controls unexposed, sick), 2012 11.47[0.76; 2.85]-62not evaluable Language disorders/delay Nulman (Controls unexposed, sick), 2012 11.49[0.77; 2.89]-62not evaluable ADHD (Attention deficit hyperactivity disorder): Diagnosis Heuvelman, 2023 10.97[0.48; 1.96]-818not evaluable ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk Heuvelman, 2023 10.97[0.48; 1.96]-818not evaluable Cognitive developmental disorders/delay (> 6 years old) Heuvelman, 2023 10.99[0.33; 2.95]-818not evaluable Severe cognitive developmental delay (Mental retardation) (> 6 years old) Heuvelman, 2023 10.99[0.33; 2.95]-818not evaluable0.050.01.0

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons